Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • c-Met/HGFR
    (19)
  • Apoptosis
    (4)
  • EGFR
    (3)
  • TAM Receptor
    (3)
  • c-Kit
    (3)
  • PROTACs
    (2)
  • VEGFR
    (2)
  • Akt
    (1)
  • Antibacterial
    (1)
  • Others
    (22)
Filter
Search Result
Results for "

met-in-1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    60
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    9
    TargetMol | Peptide_Products
  • PROTAC Products
    3
    TargetMol | PROTAC
  • Natural Products
    2
    TargetMol | Natural_Products
  • Recombinant Protein
    17
    TargetMol | Recombinant_Protein
MET-IN-1
T89523
MET-IN-1 (Compound 13) is an orally active inhibitor of MET with antitumor activity.
  • Inquiry Price
Size
QTY
c-met-IN-1
T106532084836-84-8
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
  • Inquiry Price
8-10 weeks
Size
QTY
TAM&Met-IN-1
T641852412356-57-9
TAM&Met-IN-1 is a potent inhibitor of TAM and c-Met, acting on AXL (IC50: 6.1 nM), MER (IC50: 13.2 nM) and TYRO3 (IC50: 21.6 nM). TAM&Met-IN-1 can be used in anticancer studies.
  • Inquiry Price
10-14 weeks
Size
QTY
VEGFR-2/c-Met-IN-1
T80874
VEGFR-2 c-Met-IN-1 is a dual inhibitor of VEGFR-2 and c-Met, with IC50 values of 138 nM and 74 nM, respectively, demonstrating antitumor activity [1].
  • Inquiry Price
Size
QTY
PARP1/c-Met-IN-1
T871042944101-99-7
PARP1 c-Met-IN-1 (Compound 16) serves as a selective dual inhibitor targeting both PARP1 and c-Met, demonstrating IC50 values of 3.3 nM and 32.2 nM, respectively. This compound effectively induces apoptosis and causes cell cycle arrest at the G2 M phase in MDA-MB-231 cells. Furthermore, PARP1 c-Met-IN-1 displays notable antitumor activity in mouse models [1].
  • Inquiry Price
10-14 weeks
Size
QTY
c-Met-IN-15
T9990330572-32-2
c-Met-IN-15 exhibits antibacterial activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
C-Met/Axl-IN-1
T205497
C-Met Axl-IN-1 (Compound 22a) is an oral, selective type II c-Met Axl inhibitor with IC50 values of 1 nM and 10 nM, respectively. It effectively suppresses tumor cell proliferation, induces cell cycle arrest, and apoptosis (apoptosis), showcasing potent anti-tumor activity.
  • Inquiry Price
Size
QTY
c-Met-IN-12
T640802426675-70-7
c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to further enhance kinase selectivity. c-Met-IN-12 exhibits anti-tumour activity.
  • Inquiry Price
6-8 weeks
Size
QTY
c-Met-IN-16
T729781208248-23-0
c-Met-IN-16, a c-Met inhibitor, is utilized in cancer research.
  • Inquiry Price
6-8 weeks
Size
QTY
MET/PDGFRA-IN-1
T78843
MET PDGFRA-IN-1 (compound 8c) is an inhibitor of MET and PDGFRA proteins, with an IC50 of 36 μM against MET. It inhibits MET phosphorylation, induces apoptosis, and reduces proliferation in various MET-positive cell lines, showing IC50 values of 15.3 μM for AsPc-1, 19.0 μM for EBC-1, 22.0 μM for MKN-45, 25.6 μM for Mia-Paca-2, 21.0 μM for HT-29, and 31.5 μM for K562 [1].
  • Inquiry Price
Size
QTY
c-Met-IN-18
T78934
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. It is utilized in research pertaining to c-MET-driven cancers [1].
  • Inquiry Price
Size
QTY
c-Met-IN-17
T79142
c-Met-IN-17 is a potent inhibitor of c-Met kinase with an IC50 of 0.031 μM, making it relevant for anticancer research. [1]
  • Inquiry Price
Size
QTY
c-Met-IN-19
T79715
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM, demonstrating cytotoxic effects on various cancer cell lines, including A549, HT-29, SGC-7901, and MDA-MB-231, with IC50 values of 0.25, 0.36, 0.98, and 0.76 μM, respectively [1].
  • Inquiry Price
Size
QTY
c-Met-IN-10
T635902415291-03-9
c-Met-IN-10 is a potent c-Met kinase inhibitor (IC50: 16 nM). c-Met-IN-10 inhibits the activity of cancer cells A549, H460 and HT-29, and inhibits A549 cell movement by inhibiting HT-29 cell colony formation, which in turn induces apoptosis in HT-29 and A549 cells. c-Met-IN-10 can be used in anticancer studies. -Met-IN-10 is capable of being used in anticancer studies.
  • Inquiry Price
8-10 weeks
Size
QTY
c-met-in-11
T636561446324-05-5
c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).
  • Inquiry Price
6-8 weeks
Size
QTY
c-Met-IN-13
T638852377724-93-9
c-Met-IN-13 is a potent inhibitor of c-Met (IC50: 2.43 nM) that exhibits significant cytotoxicity and anti-proliferative effects against cancer cells in a concentration-dependent and time-dependent manner, demonstrating therapeutic potential against cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
c-Met/MEK1/Flt-3-IN-1
T72407
Antiproliferative Against-3 (comp 33) demonstrates significant activity against Hela (IC 50 = 0.21 µM), A549 (IC 50 = 0.39 µM), and MCF-7 (IC 50 = 0.33 µM) cell lines. Additionally, it induces apoptosis in a dose-dependent manner by arresting A549 cells in the G1 phase.
  • Inquiry Price
8-10 weeks
Size
QTY
c-Met-IN-14
T730222443380-34-3
c-Met-IN-14, a N-sulfonylamidine-based derivative, is a selective c-Met kinase inhibitor with an IC50 value of 2.89 nM. It exhibits anticancer properties by inhibiting c-Met phosphorylation and arresting the cell cycle at the G2 M phase. Additionally, c-Met-IN-14 promotes dose-dependent apoptosis in A549 cells.
  • Inquiry Price
6-8 weeks
Size
QTY
JNK-IN-8
JNK Inhibitor XVI
T26681410880-22-6
JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1 2 4 inhibitor (IC50: 4.7 18.7 1 nM) with over 10-fold selectivity compared to MNK2 and Fms, and no inhibition of Met, c-Kit, or PDGFRβ in the A375 cell line.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
met-kinase-in-2
1,6-Naphthyridin-4(1H)-one, 5-[[3-fluoro-4-[[7-(2-hydroxy-2-methylpropoxy)-4-quinolinyl]oxy]phenyl]amino]-3-phenyl-
T87952101241-90-9In house
MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM. It also possesses antitumor activity[1].
  • Inquiry Price
8-10weeks
Size
QTY
Ensartinib
T375851370651-20-9
Ensartinib (X-396) is a potent dual ALK MET inhibitor with IC50 values of <0.4 nM for ALK and 0.74 nM for MET.
  • Inquiry Price
1-2 weeks
Size
QTY
sitravatinib
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.
  • Inquiry Price
Size
QTY
c-Kit-IN-1
PDGFR inhibitor 1, DCC-2618
T43321225278-16-9
c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
P-gb-IN-1
T775752632874-49-6
P-gb-IN-1 is a potent P-glycoprotein (P-gp) inhibitor that exhibits reverse activity by inhibiting P-gp outflow. P-gb-IN-1 has been shown to inhibit P-gp by hydrogen bonding with residues Asn 721 and Met 986. P-gb-IN-1 showed low toxicity in MCF-7 ADR cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale